Cencora, Inc.
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cencora, Inc. and other ETFs, options, and stocks.About COR
Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments.
COR Key Statistics
Stock Snapshot
As of today, Cencora, Inc.(COR) shares are valued at $342.96. The company's market cap stands at 66.54B, with a P/E ratio of 42.92 and a dividend yield of 65.8%.
On 2025-12-18, Cencora, Inc.(COR) stock opened at $341.78, reached a high of —, and a low of —.
The Cencora, Inc.(COR)'s current trading volume is 0, compared to an average daily volume of 1.52M.
In the last year, Cencora, Inc.(COR) shares hit a 52-week high of $377.54 and a 52-week low of $223.92.
In the last year, Cencora, Inc.(COR) shares hit a 52-week high of $377.54 and a 52-week low of $223.92.
COR News
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended selling BP p.l.c. (NYSE:BP) . On the earnings front, BP, on Nov. 4, posted third-quarter adjusted...
Cencora, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Allen Lutz from Bank of America Securities maintained a Hold r...
Cencora, Inc. (NYSE:COR) on Monday agreed to acquire the majority stake it does not own in OneOncology from TPG and other shareholders for. Cencora stock is sh...
Analyst ratings
70%
of 20 ratingsMore COR News
Backs FY26 revenue growth view 5%-7% vs. FY25 revenue $321.3B. FY26 consensus $340.56B. The company said, “To reflect Cencora’s (COR) expectations for continued...
Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...
Cencora recently announced past investments to expand its third-party logistics network across the US and Europe, including a highly automated 500,000 square-fo...
If you are wondering whether Cencora is still worth buying after such a strong run, or if the prudent move now is to wait for a better entry price, you are in t...